Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.45 |
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19751773 | 0.92 | TSHR (0.58) | TSHRCNR1ENPP2LPAR1LPAR2 | |
| SCHEMBL19871336 | 0.92 | TSHR (0.58) | TSHRCNR1ENPP2LPAR1LPAR2 | |
| SCHEMBL16203711 | 0.92 | TSHR (0.58) | TSHRCNR1ENPP2LPAR1LPAR2 | |
| SCHEMBL279863 | 0.90 | FAAH (0.50) | TSHRCNR1ENPP2LPAR1LPAR2 | |
| SCHEMBL25110141 | 0.89 | TSHR (0.56) | TSHRCNR1ENPP2LPAR1LPAR2 | |
| SCHEMBL17635394 | 0.89 | TSHR (0.74) | TSHRCNR1HPGDMEN1KMT2A | |
| SCHEMBL26208462 | 0.88 | CASP2 (0.53) | TSHRCNR1ENPP2LPAR1LPAR2 | |
| SCHEMBL20470066 | 0.88 | FAAH (0.49) | TSHRCNR1ENPP2LPAR1LPAR2 | |
| SCHEMBL13501556 | 0.88 | CNR1 (0.67) | TSHRCNR1ENPP2LPAR1LPAR2 | |
| SCHEMBL26700382 | 0.87 | CNR1 (0.58) | TSHRCNR1ENPP2LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9861705-B2 | Conjugates of an IL-2 moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2018-01-09 | — | — | US | disclosed |
| US-9421275-B2 | Oligomer-calcimimetic conjugates and related compunds | NEKTAR THERAPEUTICS (US) | 2016-08-23 | — | — | US | disclosed |
| US-20140328791-A1 | Conjugates of an IL-2 Moiety and a Polymer | NEKTAR THERAPEUTICS | 2014-11-06 | — | — | US | disclosed |
| US-20140323565-A1 | Oligomer-Calcimimetic Conjugates and Related Compunds | NEKTAR THERAPEUTICS (US) | 2014-10-30 | — | — | US | disclosed |
| US-8435505-B2 | Pharmaceutical compositions and methods for delivering such compositions | NEKTAR THERAPEUTICS (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120258912-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR DELIVERING SUCH COMPOSITIONS | NEKTAR THERAPEUTICS (US) | 2012-10-11 | — | — | US | disclosed |
| US-8133865-B2 | Two polymer chains (especially polyethylene oxide) connected to each other through a fluorenedicarbamoylmethyl group, which in turn is connected to an amine active agent by a releasable carbamate linkage; increased in vivo half-life | NEKTAR THERAPEUTICS (US) | 2012-03-13 | — | — | US | disclosed |
| US-20080234193-A1 | Von Willebrand factor-and factor VIII-polymer conjugates having a releasable linkage | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140328791-A1 | Conjugates of an IL-2 Moiety and a Polymer | IL2, IL2RA, ILF2 | TSHR 2859/4885CNR1 4173/4885ENPP2 544/4885 |
| US-20120258912-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR DELIVERING SUCH COMPOSITIONS | ABCG2, SI, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TSHR 3934/4885CNR1 1450/4885ENPP2 2258/4885 |
| US-20080234193-A1 | Von Willebrand factor-and factor VIII-polymer conjugates having a releasable linkage | F8, F13A1, F13B | TSHR 4142/4885CNR1 4798/4885ENPP2 228/4885 |
| US-20140323565-A1 | Oligomer-Calcimimetic Conjugates and Related Compunds | CALCR, CALCB, CALCA | TSHR 1757/4885CNR1 1084/4885ENPP2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.